See more : Kwan On Holdings Limited (1559.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Praxis Precision Medicines, Inc. (PRAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Praxis Precision Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Galderma Group N (GALD.SW) Income Statement Analysis – Financial Results
- Ultra Brands Ltd. (ULTA.CN) Income Statement Analysis – Financial Results
- Ching Chan Optical Technology Co., Ltd. (2070.TWO) Income Statement Analysis – Financial Results
- Shenzhen Batian Ecotypic Engineering Co., Ltd. (002170.SZ) Income Statement Analysis – Financial Results
- Guangzhou Baiyun International Airport Co., Ltd. (600004.SS) Income Statement Analysis – Financial Results
Praxis Precision Medicines, Inc. (PRAX)
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| Gross Profit | 2.45M | -1.17M | -1.59M | -746.00K | -679.00K | -1.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.77M | 155.04M | 120.26M | 44.98M | 29.56M | 18.82M |
| General & Administrative | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Other Expenses | 0.00 | 957.00K | 271.00K | 140.00K | 0.00 | -3.65M |
| Operating Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Cost & Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Interest Income | 3.10M | 0.00 | 271.00K | 140.00K | 193.00K | 92.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.00K |
| Depreciation & Amortization | 432.00K | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| EBITDA | -125.94M | -212.86M | -165.47M | -61.08M | -34.92M | -26.27M |
| EBITDA Ratio | -5,146.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.37M | -214.99M | -167.33M | -61.97M | -35.79M | -22.72M |
| Operating Income Ratio | -5,164.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.10M | 957.00K | 271.00K | 140.00K | 193.00K | -3.68M |
| Income Before Tax | -123.28M | -214.03M | -167.06M | -61.83M | -35.60M | -26.40M |
| Income Before Tax Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -957.00K | -182.00K | -8.00K | -84.00K | 133.00K |
| Net Income | -123.28M | -213.07M | -166.88M | -61.82M | -35.51M | -26.54M |
| Net Income Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| EPS Diluted | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Avg Shares Out | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
| Weighted Avg Shares Out (Dil) | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Praxis Precision Medicines to Participate in Upcoming April Conferences
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis (PRAX) Surges on Positive Epilepsy Study Results
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Source: https://incomestatements.info
Category: Stock Reports